Morgan Stanley sees Centessa’s ORX750 as ‘best-in-class’ after competitor data

After Alkermes (ALKS) announced data from its VIBRANCE-2 study of alixorexton in Narcolepsy Type 2, Morgan Stanley noted that the reported MWT score of 9.3 minutes at Week 8 was slightly below Centessa’s (CNTA) results with ORX750, only at Week 2. The firm, which continues to see evidence positioning Centessa’s ORX750 as “best-in-class,” keeps an Overweight rating and $27 price target on Centessa shares.